139 related articles for article (PubMed ID: 6406688)
1. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
Trachtenberg J
J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
[TBL] [Abstract][Full Text] [Related]
2. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
Winfield H; Trachtenberg J
J Urol; 1984 Jun; 131(6):1107-9. PubMed ID: 6427477
[TBL] [Abstract][Full Text] [Related]
3. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
[TBL] [Abstract][Full Text] [Related]
4. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
Smith JA
J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
6. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Labrie F; Dupont A; Belanger A; Lachance R
J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
[TBL] [Abstract][Full Text] [Related]
7. Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
Sasagawa I; Kubota Y; Nakada T; Suzuki H; Hirano J; Sugano O; Kato H; Imamura A; Mastushita K; Onmura Y; Saito M; Adachi M
Int Urol Nephrol; 1998; 30(6):745-53. PubMed ID: 10195870
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
[TBL] [Abstract][Full Text] [Related]
9. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
[TBL] [Abstract][Full Text] [Related]
13. Endocrine and clinical effects of leuprolide in prostatic cancer.
Vance MA; Smith JA
Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
[TBL] [Abstract][Full Text] [Related]
14. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients].
Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K
Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
[TBL] [Abstract][Full Text] [Related]
17. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
[TBL] [Abstract][Full Text] [Related]
18. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.
Glode LM; Smith JA
J Urol; 1987 Jan; 137(1):57-60. PubMed ID: 3098990
[TBL] [Abstract][Full Text] [Related]
19. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
20. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
